PT - JOURNAL ARTICLE AU - Renumathy Dhanasekaran AU - David Kooby AU - Charles Staley AU - John Kauh AU - Jaime Montilla-Soler AU - Bruce Barron AU - Hyun Kim TI - Radioembolization for unresectable chemorefractory hepatic metastases – Safety and efficacy DP - 2009 May 01 TA - Journal of Nuclear Medicine PG - 290--290 VI - 50 IP - supplement 2 4099 - http://jnm.snmjournals.org/content/50/supplement_2/290.short 4100 - http://jnm.snmjournals.org/content/50/supplement_2/290.full SO - J Nucl Med2009 May 01; 50 AB - 290 Objectives To assess safety and efficacy of radioembolization with Y-90 for unresectable and chemorefractory hepatic metastases. Methods Consecutive patients with unresectable chemorefractory metastases who received only transcatheter radioembolization with Yittrium 90 between 2003 & 2008 were studied. RECIST criteria used to assess treatment response.NCI CTACEv3 criteria used to record complications Survival analysis performed with Kaplan-Meier method. Results 47 patients were included in the study ,they underwent 68 radioembolization sessions. Mean cumulative radiation dose was 58.1 mCi ± 22.1. Primary tumors were colorectal, neuroendocrine, melanoma, breast ca. and sarcoma. Median survival from time of diagnosis of hepatic metastases & from first embolization were 398 days (95% CI 242-558) & 202 days(95% CI142-261). Survival from the time of diagnosis of hepatic metastases & first radioembolization at 6 months, 12 months and 18 months were 75%, 55%, 35% & 51%, 21%, 12%. The imaging done 1 month post- procedure showed progressive disease in 12.5% (6/47) of the patients. The mean progression-free duration was 158.2 days (SD 198).1 patient died within 30 days of therapy, grade 5 CTCAEv3. 1 patient developed grade 4 CTAE complication (hepatic encephalopathy). Conclusions Radioembolization as a palliative therapy for unresectable and chemorefractory hepatic metastases is safe and feasible.